PHT Sets ePRO Industry Milestone with 400th Electronic Clinical Trial
News Sep 09, 2009
PHT Corporation accomplished a significant new ePRO industry milestone as it announced its 400th clinical trial. PHT is a provider of ePRO solutions used in pharmaceutical and biotechnology clinical trials worldwide.
PHT President and CEO Phil Lee said, “This is a remarkable achievement not just for PHT, but for the industry. Our customers have made ePRO the standard because of the unsurpassed data quality that it yields. Pharmaceutical and biotech sponsors also recognize eDiaries as required technology for fast, safe, and economical trials for developing medical breakthroughs that improve the lives of millions of patients.”
Mr. Lee also credited PHT’s organization, saying, “The vision, professionalism and dedication of PHT’s employees around the world allowed us to realize this unsurpassed milestone.”
Among the significant factors in PHT’s reaching its 400th clinical trial:
Experience – The Company is recognized for its PMI-based processes, expertise in global logistics, consistent project management teams throughout a trial, and its 24x7 international Help Desk.
Product Suite – PHT offers the widest range of ePRO solutions to deliver the voice of the patient directly and without distortion. These products include the LogPad® and SitePad® Tablet.
Scientific guidance throughout a trial – PHT’s science team uses a consultative, best practices approach customized for each individual trial.
Patient Safety – PHT’s capabilities include automatic notification of missed eDiary entries as well as direct messaging to both subjects and sites.
ISO Certification – PHT is the only handheld ePRO provider to achieve ISO 9001:2000 certification and has maintained the world-class standard for the past six years with two re-certifications. PHT’s practices for continuous improvement include audit success history, issue resolution, and clear documentation.
Study Archive – PHT’s Study Archive provides trial documentation in PDF format and eSource data in XML format, on media that is guaranteed by the manufacturer to be readable for 100 years. It complies with US, Japan, and European Union requirements for data retention and trial reconstruction.
Advanced Prostate Cancer: EMA Approves Abiraterone Combined With Hormone Therapy as First-line TreatmentNews
The prostate cancer drug abiraterone has been approved by the European Medicines Agency in combination with standard hormone therapy for use as a first-line treatment for advanced prostate cancer.READ MORE
Diabetes Drug Could Be Re-purposed to Help End Transplant RejectionNews
A diabetes drug currently undergoing development could be repurposed to help end transplant rejection, without the side-effects of current immunosuppressive drugs.READ MORE
Study Shows Cancer Patients Are Choosing Less Severe Side Effects Over Treatment EfficacyNews
When choosing their preferred treatment, people with chronic lymphocytic leukemia (CLL) place the highest value on medicines that deliver the longest progression-free survival, but are willing to swap some drug efficacy for a reduced risk of serious adverse events according to a new study.READ MORE